Skip to main content
SpringerLink
Log in

Afatinib/durvalumab

Various toxicities, drug resistance and lack of efficacy: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Fang YF, et al. Afatinib and osimertinib in lung adenocarcinoma harbored EGFR T751_I759delinsS mutation: A case report. Thoracic Cancer 12: 3429-3432, No. 24, Dec 2021. Available from: URL: http://doi.org/10.1111/1759-7714.14215

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Afatinib/durvalumab. Reactions Weekly 1906, 26 (2022). https://doi.org/10.1007/s40278-022-14916-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-14916-8

Search

Navigation